
WHAT WE CLAIM

1. Co-crystals of compounds of formula **1**



1

wherein

R^1 is C_{1-6}-alkyl, C_{1-6}-haloalkyl, O-C_{1-6}-haloalkyl, halogene;

m is 1, 2 or 3;

R^{2a} and R^{2b} are each independently selected from H, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, C_{3-6}-cycloalkyl, COO-C_{1-6}-alkyl, O-C_{1-6}-alkyl, $CONR^{2b.1}R^{2b.2}$, halogene;

$R^{2b.1}$ is H, C_{1-6}-alkyl, C_{0-4}-alkyl-C_{3-6}-cycloalkyl, C_{1-6}-haloalkyl;

$R^{2b.2}$ is H, C_{1-6}-alkyl;


or $R^{2b.1}$ and $R^{2b.2}$ are together a C_{3-6}-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom

R^3 is H, C_{1-6}-alkyl;

X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succinate, ~~benzoate~~ and p-toluenesulphonate;

ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, l-lysine, l-proline, or hydrates or hydrochlorides of the same.

9. Salts of compounds of formula **1**,



1

wherein R^1, m, R^{2a}, R^{2b}, R^3 are defined as in one of claims 1 to 8 and

X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succinate, ~~benzoate~~ and p-toluenesulphonate;


j is ~~0,~~ 0.5, 1, 1.5 or 2.


10. Salts of compounds of formula **1**, wherein R^1, m, R^{2a}, R^{2b}, R^3 are defined as in one of claims 1 to 8 and


X is an anion selected from the group consisting of chloride or dibenzoyltartrate


j is 1 or 2.


11. Co-crystals according to one of claims 1 to 8 or salts according to claim 9 or 10, wherein the compound is selected from the group consisting of







































































































and




12. Co-crystals according to claim 8, wherein the compound is




*$(HCl)_2$, and the co-crystal former is selected from the group consisting of ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, hydrated l-lysine and l-proline.

13. Salt according to claim 9, wherein the salt is




*(S)-(S)-(+)-2,3-dibenzoyl-tartaric acid.

14. Salt according to claim 9, wherein the salt is




*$(HCl)_2$.

15. Salt according to claim 9, wherein the salt is



*$(HCl)_2$*1.5 H_2O.


16. Salt according to claim 9, wherein the salt is



*$(HCl)_2$*Methyl-isobutyl-ketone.


~~11. Salts according to claim 9 or 10 used for the manufacture of a co-crystal according to one of claims 1 to 8.~~

~~12. Compounds of formula I12 for the manufacture of a co-crystal or a salt of formula 1 according to one of claims 1 to 11.~~




~~I12~~

~~13~~17. Compounds of formula **I13** ~~for the manufacture of a co-crystal or a salt of formula 1 according to one of claims 1 to 11.~~




I13

~~14~~18. Compounds of formula **I14** ~~for the manufacture of a co-crystal or a salt of formula 1 according to one of claim 1 to 11~~.




I14

~~15~~19. Compounds ~~of~~ of formula **I3'-Me** ~~for the manufacture of a co-crystal or a salt of formula 1 according to one of claim 1 to 11.~~




I3'-Me

~~16. Compounds of formula I4' for the manufacture of a co-crystal or a salt of formula 1 according to one of claim 1 to 11.~~



~~I4'~~

~~17. Compounds of formula A' for the manufacture of a co-crystal or a salt of formula 1 according to one of claim 1 to 11.~~



~~A'~~

~~18~~20. A pharmaceutical composition comprising at least one co-crystal or salt of a compound of formula 1 according to any one of claims 1 to ~~14~~16 and a pharmaceutically acceptable carrier.

~~19~~21. A co-crystal or salt of a compound of formula 1, according to one of claims 1 to ~~10~~14, as a medicament.

~~20~~22. Use of a co-crystal or salt of a compound of formula 1, according to one of claims 1 to ~~10~~14, for the manufacture of a medicament for the prevention or treatment of a wide variety of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (including viruses), autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis as well as age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema.

~~21~~23. A co-crystal or salt of a compound of formula 1, according to one of claims 1 to ~~10~~14, for use in the prevention or treatment of a wide variety of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (including viruses), autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis as well as age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema.